BioVectis

Startup

BioVectis is a innovator in the Life Sciences R&D sector, specializing in the development, manufacturing, and marketing of uniqe methods and tools to study proteins and nucilec acds structure/function corealtion. 

Our flagship product, the DNAPointer® System, engineered for slab gel electrophoresis, it achieves unparalleled gel temperature control during the separation with an accuracy of ±0.2°C at 2-60°C range, making it the world’s most precise and reproducible electrophoretic separation platform. This exceptional precision enables the separation, for example nucleic acid (RNA or ssDNA) spatial conformers differing by as little as 0.6 kcal/mol in free energy under native conditions. Researchers can thus distinguish unique native conformers of the same RNA or ssDNA molecule and investigate their distinct biological properties, such as nucleic acid-protein interactions and functional complexes foramtion. 

The DNAPointer® System also excels in ultra-precise analysis and sample optimization for complex biomolecular interactions, including native protein-protein, protein-membrane, and protein-nucleic acid complexes. This makes it an indispensable tool for preparing samples for advanced structural and compound characterization techniques, such as cryo-electron microscopy (cryo-EM), mass spectrometry (MS), next-generation sequencing (NGS), nuclear magnetic resonance (NMR), and biological assays.

BioVectis Research Portfolio

In partnership with leading academic institutions, BioVectis is pioneering a robust portfolio of research projects focused on advancing treatments and diagnostics in immune-oncology, autoimmune diseases, and veterinary medicine. Below is an overview of our key initiatives:

Scutum_O: Immuno-Oncology

Objective: Enhance the precision and efficacy of cancer neoepitope identification to support the development of more effective personalized therapeutic cancer vaccines.
Description: Scutum_O leverages a cutting-edge protein analytical platform to identify tumour-specific neoepitopes, enabling the design of more effective personalised therapeutic cancer vaccines.

Appus: Peptide-Based Therapeutics for Autoimmune Diseases

Objective: Develop a novel polypeptide drug candidate for autoimmune and inflammatory conditions.
Description: Appus is a preclinical-stage therapeutic demonstrating significant promise in the Collagen-Induced Arthritis (CIA) mouse model and a pilot study for acute wound treatment in pigs. This project aims to deliver targeted, high-efficacy solutions for patients with autoimmune and inflammatory disorders.

AgePlex: Epigenetic Age Estimation Assay

Objective: Provide a streamlined in vitro diagnostic tool for accurate human epigenetic age estimation.
Description: AgePlex utilizes just five epigenetic markers to deliver an accuracy of ±3.5 years, offering a reliable and efficient solution for aging research. This assay supports applications in personalized medicine and longevity studies.

Scutum_N: Veterinary Vaccine for Newcastle Disease Virus

Objective: Develop a recombinant viral vaccine targeting Newcastle Disease Virus (NDV) in poultry.
Description: Scutum_N is a globally unique vaccine candidate expressing both critical NDV surface protein genes (F and HN). Field validations confirm exceptional performance, with over 98% efficacy and 100% safety, positioning it as a leading solution for poultry health.

Vela-Med: Real-Time Diagnostic Platform

Objective: Enable real-time detection of gut inflammatory conditions through volatile organic compound (VOC) analysis in human breath.
Description: Vela-Med is an innovative in vitro diagnostic platform that analyses human breath in real time, at the bedside, achieving an area under the curve (AUC) exceeding 0.98 in pivotal clinical studies. This technology offers unparalleled diagnostic potential for rapid, non-invasive identification of gut inflammatory conditions.

BioVectis is actively seeking R&D partners and Investors interested in supporting the scaling up our LS R&D tools sales and accelerating R&D projects.

We are proactively pursuing strategic partnerships and opportunities, including:

• Research Collaborators: To advance our research initiatives.
• Distributors: To broaden the global distribution of our life science R&D tools.
• Investors: Committed to fuelling the expansion of our innovative solutions, driving sales growth, and accelerating our commercial success.

website